Compare D R Horton Inc (DHI) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Medtronic PLC — how do they compare? D R Horton Inc trades at $150.79 (market cap $42.18B), while Medtronic PLC trades at $90.61 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 2.8× D R Horton Inc's market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| DHI | MDT | |
|---|---|---|
Market Cap | $42.18B | $116.07B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $105.35 |
52-Week Low | $132.53 | $73.75 |
Enterprise Value | $47.28B | $134.82B |
Dividend Yield | 1.19% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $146.49, down slightly by 0.12% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $3.20, beating estimates, but revenue guidance for FY2026 was lowered. Valuation ratios appear reasonable with a P/E of 14.37 and P/S of 1.31. Operating cash flow remains strong at $3.42B for 2025, though net cash flow was negative due to significant financing outflows.
The outlook is mixed; disciplined execution supports margins, but weak housing demand and elevated mortgage rates pose headwinds. Analyst consensus is a Buy with a $153 target, offering modest upside. Key risks include persistent affordability pressures and competitive threats from disruptors like Boxabl.
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
